Skip to main content

Table 4 Antimicrobial regimens for the treatment of Acinetobacter baumannii bacteremic pneumonia (appropriate antibiotics)

From: Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia

Main agents useda,b

No. (%) of patients

(n = 151)

APACHE II score, median (IQR)d

No. (%) of patients

Combination therapye

14-Day

Mortality

P-value

28-Day

Mortality

P-value

Anti-pseudomonas penicillin-based therapy

13 (8.6)

245 (19–29)

8 (61.5)

6 (46.2)

0.513

8 (61.5)

.319

Anti-pseudomonas cephalosporin-based therapy

31 (20.5)

25 (19–32)

24 (77.4)

10 (32.3)

0.479

12 (38.7)

.229

Carbapenem-based therapy

59 (39.1)

25 (18–28)

25 (42.4)

20 (33.9)

0.434

28 (47.5)

.861

Colistin-based therapy

55 (36.4)

25 (19–29)

49 (89.1)

28 (50.9)

0.012

33 (60.0)

.030

Tigecycline-based therapy

54 (35.8)

28 (22–32)

46 (85.2)

28 (51.9)

0.008

32 (59.3)

.045

Fluoroquinolone-based therapy

7 (4.6)

25 (12–36)

3 (42.9)

4 (57.1)

0.278

4 (57.1)

.633

Sulbactam-based therapy

24 (15.9)

26 (22–28)

13 (54.2)

7 (29.2)

0.344

10 (41.7)

.475

Carbapenem + colistin-based therapy

15 (9.9)

24 (18–28)

6 (40.0)

9 (60.0)

0.061

11 (73.3)

.041

Carbapenem + tigecycline-based therapy

12 (8.0)

25 (22–28)

7 (58.3)

9 (75.0)

0.006

10 (83.3)

.011

Carbapenem + sulbactam-based therapy

6 (4.0)

25 (22–28)

5 (83.3)

4 (66.7)

0.200

5 (83.3)

.107

Colistin + tigecycline-based therapy

25 (16.6)

27 (20–32)

12 (48.0)

14 (56.0)

0.039

15 (60.0)

.202

Carbapenem + colistin + tigecycline-based therapy

4 (2.7)

24 (20–28)

2 (50.0)

4 (100.0)

0.019

4 (100.0)

.052

Antimicrobial regimensc

 Anti-pseudomonas penicillin only

5 (3.3)

24 (19–30)

 

2 (40.0)

1.000

4 (80.0)

.198

 Anti-pseudomonas cephalosporin only

7 (4.6)

23 (16–30)

 

2 (28.6)

0.711

2 (28.6)

.444

 Carbapenem + colistin

9 (6.0)

24 (18–26)

 

4 (44.4)

0.730

6 (66.7)

.315

 Carbapenem + tigecycline

5 (3.3)

25 (26–28)

 

3 (60.0)

0.366

3 (60.0)

.673

 Carbapenem + sulbactam

1 (0.7)

17

 

0

1.000

0

1.000

 Carbapenem + tigecycline + colistin

2 (1.3)

17, 22

 

2 (100)

0.141

2 (100)

.232

 Tigecycline only

8 (5.3)

29 (28–33)

 

5 (62.5)

0.155

5 (62.5)

.484

 Colistin + tigecycline

13 (8.6)

29 (22–38)

 

7 (53.9)

0.210

7 (53.9)

.678

  1. aAn antimicrobial agent (or antimicrobial agents)-based therapy denotes the corresponding antimicrobial agent(s) alone or in combination with other antimicrobial agent(s)
  2. b“Colistin” denotes intravenous colistin only. Inhaled colistin is not included
  3. cNot in combination with other antimicrobial agents
  4. dIQR, interquartile range. When the case number is less than 4, the APACHE II score for each case is shown
  5. eCombination therapy is defined as administration of more than one antimicrobial agent
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us